FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955762220> ?p ?o ?g. }

• W2955762220 abstract "Introduction: Jounce has generated cell type-specific gene signatures as a means of probing The Cancer Genome Atlas and other large datasets to identify targets that may be important immune checkpoints. Using a tumor-associated macrophage (TAM) gene signature, we have found a strong correlation and coherence between TAMs and LILRB2 (leukocyte immunoglobulin like receptor B2; ILT4) across multiple tumors types. LILRB2 is a myeloid cell surface receptor containing four extracellular immunoglobulin domains, a transmembrane domain, and three cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Ligation of LILRB2 on myeloid cells, via its endogenous ligands (classical MHC I molecules [e.g. HLA-A, HLA-B] and non-classical MHC I molecules [e.g. HLA-G]), provides a negative signal that inhibits stimulation of an immune response. HLA-G is recognized as an important immunosuppressive molecule playing a role in maternal-fetal tolerance and being overexpressed in cancer - often associated with advanced disease stage and poor prognosis. As tumor-associated macrophages are known to suppress the anti-cancer immune response, these findings provide rationale for targeting LILRB2. Methods and Results: We have generated a panel of monoclonal antibodies that bind specifically to LILRB2, but not other LILR family members, and can block binding of LILRB2 to MHC I molecules (i.e. HLA-A and HLA-G). In vitro differentiated monocyte-derived macrophages (MDMs) cultured for 24h in the presence of anti-LILRB2 antibodies and lipopolysaccharide (LPS) show polarization toward a more inflammatory phenotype - secreting higher levels of TNF-α and IL-6 with decreased amounts of IL-10 and CCL2 as compared to an isotype control antibody. NanoString mRNA analysis revealed that, in the absence of LPS or any additional stimuli, MDMs cultured with anti-LILRB2 antibodies showed gene changes consistent with inflammatory or M1-like polarization of macrophages. Anti-LILRB2 antibodies were also evaluated in human tumor histoculture and induced pharmacodynamic responses consistent with macrophage and T cell activation in a variety of tumor types. While mice do not express LILRB2 specifically, they do express a LILRB-like molecule known as Pirb. Mice that are deficient in Pirb display resistance to mouse colon 38 (MC-38) tumor growth suggesting this pathway functions as immune checkpoint in cancer. Conclusions: Based on these preclinical data, JTX-8064, a high affinity LILRB2-specific humanized antagonist monoclonal antibody, is being developed as an immunotherapeutic to reprogram suppressive macrophages within the tumor microenvironment. Citation Format: Heather Cohen, Yasmin Hashambhoy-Ramsay, Lauren R. Pepper, Jeffrey Y. Smith, Margaret Willer, Kevin Guay, Vikki Spaulding, Kristin O9Malley, Monica Gostissa, Abha Dhaneshwar, Edward C. Stack, Alessandro Mora, Donald R. Shaffer. Preclinical evaluation of JTX-8064, an anti-LILRB2 antagonist antibody, for reprogramming tumor-associated macrophages [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5007." @default.
• W2955762220 created "2019-07-12" @default.
• W2955762220 creator A5012820346 @default.
• W2955762220 creator A5012978769 @default.
• W2955762220 creator A5022250849 @default.
• W2955762220 creator A5023307099 @default.
• W2955762220 creator A5030308573 @default.
• W2955762220 creator A5048112219 @default.
• W2955762220 creator A5053827974 @default.
• W2955762220 creator A5059373950 @default.
• W2955762220 creator A5062762511 @default.
• W2955762220 creator A5063212072 @default.
• W2955762220 creator A5066035608 @default.
• W2955762220 creator A5081850457 @default.
• W2955762220 creator A5085278950 @default.
• W2955762220 date "2019-07-01" @default.
• W2955762220 modified "2023-09-26" @default.
• W2955762220 title "Abstract 5007: Preclinical evaluation of JTX-8064, an anti-LILRB2 antagonist antibody, for reprogramming tumor-associated macrophages" @default.
• W2955762220 doi "https://doi.org/10.1158/1538-7445.sabcs18-5007" @default.
• W2955762220 hasPublicationYear "2019" @default.
• W2955762220 type Work @default.
• W2955762220 sameAs 2955762220 @default.
• W2955762220 citedByCount "0" @default.
• W2955762220 crossrefType "proceedings-article" @default.
• W2955762220 hasAuthorship W2955762220A5012820346 @default.
• W2955762220 hasAuthorship W2955762220A5012978769 @default.
• W2955762220 hasAuthorship W2955762220A5022250849 @default.
• W2955762220 hasAuthorship W2955762220A5023307099 @default.
• W2955762220 hasAuthorship W2955762220A5030308573 @default.
• W2955762220 hasAuthorship W2955762220A5048112219 @default.
• W2955762220 hasAuthorship W2955762220A5053827974 @default.
• W2955762220 hasAuthorship W2955762220A5059373950 @default.
• W2955762220 hasAuthorship W2955762220A5062762511 @default.
• W2955762220 hasAuthorship W2955762220A5063212072 @default.
• W2955762220 hasAuthorship W2955762220A5066035608 @default.
• W2955762220 hasAuthorship W2955762220A5081850457 @default.
• W2955762220 hasAuthorship W2955762220A5085278950 @default.
• W2955762220 hasConcept C203014093 @default.
• W2955762220 hasConcept C502942594 @default.
• W2955762220 hasConcept C86803240 @default.
• W2955762220 hasConcept C8891405 @default.
• W2955762220 hasConceptScore W2955762220C203014093 @default.
• W2955762220 hasConceptScore W2955762220C502942594 @default.
• W2955762220 hasConceptScore W2955762220C86803240 @default.
• W2955762220 hasConceptScore W2955762220C8891405 @default.
• W2955762220 hasLocation W29557622201 @default.
• W2955762220 hasOpenAccess W2955762220 @default.
• W2955762220 hasPrimaryLocation W29557622201 @default.
• W2955762220 hasRelatedWork W1779462464 @default.
• W2955762220 hasRelatedWork W1964444828 @default.
• W2955762220 hasRelatedWork W1978921205 @default.
• W2955762220 hasRelatedWork W1982661800 @default.
• W2955762220 hasRelatedWork W1983363207 @default.
• W2955762220 hasRelatedWork W1991468383 @default.
• W2955762220 hasRelatedWork W2035774630 @default.
• W2955762220 hasRelatedWork W2056973714 @default.
• W2955762220 hasRelatedWork W2077860472 @default.
• W2955762220 hasRelatedWork W2085576104 @default.
• W2955762220 hasRelatedWork W2140516324 @default.
• W2955762220 hasRelatedWork W2158985672 @default.
• W2955762220 hasRelatedWork W2465380765 @default.
• W2955762220 hasRelatedWork W2522468074 @default.
• W2955762220 hasRelatedWork W2564700674 @default.
• W2955762220 hasRelatedWork W2780966665 @default.
• W2955762220 hasRelatedWork W2885636541 @default.
• W2955762220 hasRelatedWork W2914317578 @default.
• W2955762220 hasRelatedWork W3138521592 @default.
• W2955762220 hasRelatedWork W3179450000 @default.
• W2955762220 isParatext "false" @default.
• W2955762220 isRetracted "false" @default.
• W2955762220 magId "2955762220" @default.
• W2955762220 workType "article" @default.